Published
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as Director of the genitourinary cancer research group, Professor, and co-Director of the Cancer Signaling Network program at Yale Cancer Center, New Haven, Connecticut. In this 10-minute talk, he discusses advancements in treating urothelial carcinoma, emphasizing innovative therapies for BCG-refractory, recurrent, and metastatic disease.
- Category
- Oncology
Be the first to comment
Up Next
-
05:24
Clinical Trials in Oncology: Episode 2
-
04:44
Clinical Trials in Oncology: Episode 3
-
07:24
Where We Were and Where We Are in NMIBC Trials and Therapies
-
04:23
Only 7% of Patients With Cancer Participate in Clinical Trials: Far From Adequate
-
05:56
From Clinical Trials to Clinical Practice: COX-2 Inhibition
-
04:31
Clinical Trials in Oncology: Episode 1
-
Class-59: Understanding OR, HR, CI & p-Values in Oncology Clinical Trials
-
08:50
The SunRISe Trials and TAR-200: Bladder-Sparing Therapies for NMIBC
-
04:42
Clinical Trials with MN Oncology
-
16:40
Important Clinical Trials In Cardiology
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
